Overview

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

Status:
RECRUITING

Trial end date:
2028-12-30

Target enrollment:

Participant gender:

Summary

Glumetinib combined withFruquintinib in the treatment of MET amplification or protein overexpression in third-line unresectable metastatic colorectal cancer: evaluation of efficacy and safety

Phase:

PHASE1

Details

Lead Sponsor:

Liu Huang

Treatments:

HMPL-013